Syneron Bio has completed nearly $100 million in Series A and Series A+ financing.

36Kr learned that "Syneron Bio", a macrocyclic peptide drug R & D company driven by an intelligent platform, has successively completed nearly $100 million in Series A and Series A+ financing. This round of financing was led by AstraZeneca, the AstraZeneca CICC Medical Industry Fund, and a first - tier medical fund. Institutions such as Pfizer Biotech Development Investment Fund, GL Ventures of Hillhouse Capital, WuYuan Capital, Sinovation Ventures, Lenovo Capital and Incubator Group, Gree Industrial Investment, and Xinneng Venture Capital participated in the investment. This round of financing will support the company to further enhance the R & D capabilities of its intelligent high - throughput macrocyclic peptide R & D platform, Synova™, and provide financial support for advancing multiple pipelines into the clinical stage.